Literature DB >> 17575204

"No Turning Bax" in the combined battle against prostate cancer:.

Ramji R Rajendran1, Gary D Kao.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17575204      PMCID： PMC3614077          DOI： 10.1158/1078-0432.CCR-07-0810

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


× No keyword cloud information.
  32 in total

1.  Apoptosis and bcl-2 expression in prostate cancer: significance in clinical outcome after brachytherapy.

Authors:  M J Szostak; P Kaur; P Amin; S C Jacobs; N Kyprianou
Journal:  J Urol       Date:  2001-06       Impact factor: 7.450

2.  The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer.

Authors:  J C Smith; S Bennett; L M Evans; H G Kynaston; M Parmar; M D Mason; J R Cockcroft; M F Scanlon; J S Davies
Journal:  J Clin Endocrinol Metab       Date:  2001-09       Impact factor: 5.958

Review 3.  Side effects of androgen deprivation therapy: monitoring and minimizing toxicity.

Authors:  Celestia S Higano
Journal:  Urology       Date:  2003-02       Impact factor: 2.649

4.  Targeting bcl-2 gene to delay androgen-independent progression and enhance chemosensitivity in prostate cancer using antisense bcl-2 oligodeoxynucleotides.

Authors:  M E Gleave; H Miayake; J Goldie; C Nelson; A Tolcher
Journal:  Urology       Date:  1999-12       Impact factor: 2.649

5.  The predictive value of bcl-2, bax, bcl-xL, bag-1, fas, and fasL for chemotherapy response in advanced breast cancer.

Authors:  Johanna Sjöström; Carl Blomqvist; Kristina von Boguslawski; Nils-Olof Bengtsson; Ingvil Mjaaland; Per Malmström; Björn Ostenstadt; Erik Wist; Vahur Valvere; Shinichi Takayama; John C Reed; Eero Saksela
Journal:  Clin Cancer Res       Date:  2002-03       Impact factor: 12.531

6.  Protein kinase A RIalpha antisense inhibition of PC3M prostate cancer cell growth: Bcl-2 hyperphosphorylation, Bax up-regulation, and Bad-hypophosphorylation.

Authors:  Yee Sook Cho; Meyoung-Kon Kim; Langzhu Tan; Rakesh Srivastava; Sudhir Agrawal; Yoon S Cho-Chung
Journal:  Clin Cancer Res       Date:  2002-02       Impact factor: 12.531

7.  Bcl-2 and Bax expression predict prostate cancer outcome in men treated with androgen deprivation and radiotherapy on radiation therapy oncology group protocol 92-02.

Authors:  Li Yan Khor; Jennifer Moughan; Tahseen Al-Saleem; Elizabeth H Hammond; Varagur Venkatesan; Seth A Rosenthal; Mark A Ritter; Howard M Sandler; Gerald E Hanks; William U Shipley; Alan Pollack
Journal:  Clin Cancer Res       Date:  2007-06-15       Impact factor: 12.531

8.  Bcl-2/bax mRNA expression ratio as prognostic factor in low-grade urinary bladder cancer.

Authors:  P Gazzaniga; A Gradilone; R Vercillo; O Gandini; I Silvestri; M Napolitano; L Albonici; A Vincenzoni; M Gallucci; L Frati; A M Agliano
Journal:  Int J Cancer       Date:  1996-04-22       Impact factor: 7.396

Review 9.  Hormonal therapy and radiotherapy for localized prostate cancer: who, where and how long?

Authors:  Mack Roach
Journal:  J Urol       Date:  2003-12       Impact factor: 7.450

10.  Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02.

Authors:  Gerald E Hanks; Thomas F Pajak; Arthur Porter; David Grignon; Harmart Brereton; Varagur Venkatesan; Eric M Horwitz; Colleen Lawton; Seth A Rosenthal; Howard M Sandler; William U Shipley
Journal:  J Clin Oncol       Date:  2003-11-01       Impact factor: 44.544
View more
  1 in total

1.  Differential response to zinc-induced apoptosis in benign prostate hyperplasia and prostate cancer cells.

Authors:  Michelle Yan; Karin Hardin; Emily Ho
Journal:  J Nutr Biochem       Date:  2009-07-02       Impact factor: 6.048
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.